ES2053090T3 - Antigestagenos 11beta-aril-16alfa,17alfa-ciclohexano-estra-4,9-dienos. - Google Patents

Antigestagenos 11beta-aril-16alfa,17alfa-ciclohexano-estra-4,9-dienos.

Info

Publication number
ES2053090T3
ES2053090T3 ES90250200T ES90250200T ES2053090T3 ES 2053090 T3 ES2053090 T3 ES 2053090T3 ES 90250200 T ES90250200 T ES 90250200T ES 90250200 T ES90250200 T ES 90250200T ES 2053090 T3 ES2053090 T3 ES 2053090T3
Authority
ES
Spain
Prior art keywords
estra
dienos
16alfa
ciclohexano
17alfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90250200T
Other languages
English (en)
Inventor
Helmut Dr Kasch
Gudrun Bertram
Anatoli Kurischko
Kurt Prof Dr Ponsold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2053090T3 publication Critical patent/ES2053090T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

EL INVENTO SE REFIERE A UN NUEVO 11 (BETA) ALFA), 17 (ALFA) (I). TRATA DE UN PROCEDIMIENTO PARA PRODUCIR UN COMPUESTO DE FORMULA (I); RESEÑA LA PROPIEDAD DEL COMPUESTO DE FORMULA (I) COMO ANTAGONISTA COMPETITIVO DE PROGESTERONA Y DESCRIBE LA APLICACION DEL COMPUESTO DE FORMULA (I), PARA LA PRODUCCION DE MEDICAMENTOS. SIENDO: R1 HIDROGENO O UN GRUPO METILO; R (AL CUADRADO) OCH3, SCH3, NCCCH3)2, CN, CHO, COCH3, CHOHCH3; X CHO, COCH3, CH2OH, CHOHCH3, ALQUILO, CH"CHO, ALCANOLO CH2-CHO, ALQUILO CH2O, ALCANOLO, CH2O, ALQUILO UN TIOCETAL CIDICO CON C2 O 3 EN EL ANILLO.
ES90250200T 1989-08-04 1990-08-06 Antigestagenos 11beta-aril-16alfa,17alfa-ciclohexano-estra-4,9-dienos. Expired - Lifetime ES2053090T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DD89331478A DD289541A5 (de) 1989-08-04 1989-08-04 Verfahren zur herstellung von 11beta-aryl-16 alpha, 17 alph-cyclohexanoestra-4,9-dienen

Publications (1)

Publication Number Publication Date
ES2053090T3 true ES2053090T3 (es) 1994-07-16

Family

ID=5611394

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90250200T Expired - Lifetime ES2053090T3 (es) 1989-08-04 1990-08-06 Antigestagenos 11beta-aril-16alfa,17alfa-ciclohexano-estra-4,9-dienos.

Country Status (9)

Country Link
US (1) US5166199A (es)
EP (1) EP0411734B1 (es)
JP (1) JP3061856B2 (es)
AT (1) ATE105298T1 (es)
DD (1) DD289541A5 (es)
DE (1) DE59005593D1 (es)
DK (1) DK0411734T3 (es)
ES (1) ES2053090T3 (es)
WO (1) WO1991001993A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
AU710139B2 (en) * 1996-05-01 1999-09-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The 21-substituted progesterone derivatives as new antiprogestational agents
DE19649984A1 (de) * 1996-11-22 1998-05-28 Schering Ag Cycloalkylsteroide, Verfahren zu ihrer Herstellung, diese Cycloalkylsteroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US6483580B1 (en) 1998-03-06 2002-11-19 Kla-Tencor Technologies Corporation Spectroscopic scatterometer system
AU2004217988C1 (en) * 2003-02-28 2010-06-03 Southwest Foundation For Biomedical Research Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
EP2576582B1 (en) 2010-05-26 2019-09-18 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
US8722940B2 (en) 2012-03-01 2014-05-13 Saudi Basic Industries Corporation High molybdenum mixed metal oxide catalysts for the production of unsaturated aldehydes from olefins
CN107530435A (zh) 2015-03-02 2018-01-02 科赛普特治疗学股份有限公司 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤
WO2016160969A1 (en) 2015-03-30 2016-10-06 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
ES2865334T3 (es) 2015-08-13 2021-10-15 Corcept Therapeutics Inc Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH
CA3011728A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
CA3055076C (en) 2017-03-31 2022-02-22 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
AU2018289307B2 (en) 2017-06-20 2024-02-01 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
EP4263807A2 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1427645A (en) * 1974-04-30 1976-03-10 Inst Orch Khim Im N D Zelinsko Pregnane derivative its preparation and compositions thereof
DD251142A1 (de) * 1984-11-29 1987-11-04 Akad Wissenschaften Ddr Verfahren zur herstellung von 16 alpha, 17 alpha-cyclohexano-17 beta-acetylgonen-3-onen
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DD277684A1 (de) * 1988-12-05 1990-04-11 Adw Ddr Verfahren zur herstellung von 16 alpha, 17 alpha -carbocyclischen estr-4-en-3-onen
DD277685A1 (de) * 1988-12-05 1990-04-11 Adw Ddr Verfahren zur herstellung von 16 alpha, 17 alpha -cyxlohexano-estra- 4,9-dien-3-onen

Also Published As

Publication number Publication date
WO1991001993A1 (de) 1991-02-21
JPH05509289A (ja) 1993-12-22
EP0411734B1 (de) 1994-05-04
DD289541A5 (de) 1991-05-02
EP0411734A1 (de) 1991-02-06
JP3061856B2 (ja) 2000-07-10
US5166199A (en) 1992-11-24
ATE105298T1 (de) 1994-05-15
DK0411734T3 (da) 1994-08-29
DE59005593D1 (de) 1994-06-09

Similar Documents

Publication Publication Date Title
ES2053090T3 (es) Antigestagenos 11beta-aril-16alfa,17alfa-ciclohexano-estra-4,9-dienos.
MY129970A (en) Hypolipidaemic compounds
NO308792B1 (no) Derivater av valproinsyre og 2-valproensyreamider, farmasøytisk sammensetning derav og deres anvendelse for fremstilling av et farmasøytisk preparat
ATE63124T1 (de) Prodrugverbindungen, verfahren zu deren herstellung und diese enthaltende zubereitungen mit verzoegerter freisetzung.
IL75337A (en) Polyenoic acids omega-substituted by a 4,5-dimethoxy-2-methyl-quinone or a 4,5-dimethoxy-2-methyl-phenyl group,process for the preparation thereof and pharmaceutical compositions containing the same
ATE144976T1 (de) Phenylalkansäurederivat, seine herstellung und die trennung seiner optischen isomere
NO160778C (no) Analogifremgangsmaate ved fremstilling av nye antifibrinolytisk aktive tranexaminsyreestere.
DE3363553D1 (en) Substituted alpha-(ethyl)-alpha-(phenyl)-(omega-(dialkylamino)-alkoxy)-benzyl alcohols, their acid addition salts and quaternary salts, process for their preparation, as well as medicines containing these compounds
ATE25849T1 (de) Tricyclophosphazen-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
DK0411736T3 (da) 11beta-substituerede 16alfa,17alfa-methylen-østra-4,9-dien-3-oner
ATE16278T1 (de) Hydroxybenzylamino-aryl verbindungen, verfahren zur deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen.
ATE4454T1 (de) Carboximidamid-derivate und diese enthaltende pharmazeutische praeparate, sowie ein verfahren zu ihrer herstellung.
JPS5540628A (en) Novel hydroxamic acid compound, its preparation, and medicine containing the same
ATE13882T1 (de) 1-((substituierte-naphthyl)aethyl)imidazolderivate, sie enthaltende pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung.
ATE19879T1 (de) Furyloxazolylessigsaeure-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE3676378D1 (de) Isoxazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutischen praeparate.
ES8500923A1 (es) Procedimiento para la preparacion de derivados de acido fenilacetico
MA21913A1 (fr) Procede de preparation de derives amino-oligohydroxy inhibiteurs de la renine .
DE3671444D1 (de) Biologisch aktive substanz, girolline genannt, extrahiert aus dem schwamm pseudaxinyssa cantharella, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
GB2111056A (en) Derivatives of 1, 4-thiazane-carboxylic acid preparation and utilization thereof and compositions containing same
EP0402469A4 (en) Catechol compounds, process for their preparation and pharmaceutical preparation containing same
DE3064454D1 (en) Tyrosine derivatives, a process for preparing the same and a pharmaceutical composition containing the same for treating hypertension
JPS5731643A (en) 4-methyl-3-formylpentene-1-acid alkyl, manufacture, application thereof to 4-methyl-3-formyl-3-pentene-1-acid and novel intermediate product
JPS51136648A (en) Process for preparation of 2-(1-alkenyl)-2-cyclopentenone
JPS57106633A (en) 1-halogeno-5-hydroxy-6-methylene-2-heptanol, its derivative and their preparation

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 411734

Country of ref document: ES